Background: Non-ergot dopamine agonists (NEDAs) have become the gold-standard agents for the treatment of restless legs syndrome (RLS). While the efficacy and safety of these drugs have been ...

Non-ergot derived dopamine agonists used to treat Parkinson's disease may be safe for the heart, according to preliminary research. Non-ergot derived dopamine agonists used to treat Parkinson's ...

The frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non–ergot-derived dopamine agonists ...

She continued: "Today, non-ergot derived dopamine agonists are widely used in daily clinical practice but recent studies have suggested that the non-ergot derived dopamine agonist pramipexole ...

Mirapex ER is a non-ergot dopamine agonist indicated for idiopathic Parkinson’s disease. It has high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine ...

Drug discontinued-text Requip and Requip XL are non-ergot dopamine agonists indicated for the treatment of Parkinson's disease. Requip and Requip XL are non-ergot dopamine agonists indicated for t ...

Pramipexole (Mirapex) is a non-ergot, D2 selective dopamine agonist with a fairly short half-life of 8-12 hours (somewhat longer in the elderly). Ninety percent of this drug is excreted unchanged ...

The Annals of Pharmacotherapy. 2009;43(5):813-821. Upon meta-analysis, patients taking NEDAs had significantly improved overall effect on HRQoL as compared with placebo (SMD 0.20; 95% CI 0.10 to 0 ...

Vienna, Austria - 04 December 2014: Non-ergot derived dopamine agonists used to treat Parkinson's disease may be safe for the heart, according to preliminary research presented at EuroEcho-Imaging ...